| Chronic Obstructive Airway Disease
Incruse Ellipta vs Perforomist
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Incruse Ellipta vs Perforomist with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPerforomist has a higher rate of injection site reactions vs Incruse Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Perforomist but not Incruse Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Incruse Ellipta
Perforomist
At A Glance
Oral inhalation
Once daily
Long-acting muscarinic antagonist
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation; use at the same time every day; do not use more than 1 time every 24 hours. No dosage adjustment required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Contraindications
- Severe hypersensitivity to milk proteins
- Hypersensitivity to umeclidinium or any of the excipients
- Use without an inhaled corticosteroid in patients with asthma
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, cough, arthralgia, pharyngitis, viral upper respiratory tract infection, myalgia, abdominal pain upper, toothache, contusion, tachycardia
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Eye pain, glaucoma, vision blurred, anaphylaxis, angioedema, pruritus, urticaria, dysuria, urinary retention, dysphonia, oropharyngeal pain
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Pharmacology
Long-acting muscarinic antagonist (LAMA/anticholinergic); competitively and reversibly inhibits M3 receptors at airway smooth muscle to produce bronchodilation lasting longer than 24 hours after once-daily oral inhalation.
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Incruse Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Incruse Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Incruse Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Incruse Ellipta.
No savings programs available for Perforomist.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Incruse ElliptaView full Incruse Ellipta profile
PerforomistView full Perforomist profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.